Cardio Diagnostics
Cardio Diagnostics
CDIO
NASDAQ
0.40
USD
-2.44%
About
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine.
Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases.
HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 127.1K |
| Three Month Average Volume | 4.4M |
| High Low | |
| Fifty-Two Week High | 3.56 USD |
| Fifty-Two Week Low | 0.171 USD |
| Fifty-Two Week High Date | 02 Jan 2024 |
| Fifty-Two Week Low Date | 26 Oct 2023 |
| Price and Volume | |
| Current Price | 0.375 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -19.33% |
| Thirteen Week Relative Price Change | -49.42% |
| Twenty-Six Week Relative Price Change | -80.62% |
| Fifty-Two Week Relative Price Change | -45.58% |
| Year-to-Date Relative Price Change | -87.28% |
| Price Change | |
| One Day Price Change | -2.60% |
| Thirteen Week Price Change | -45.86% |
| Twenty-Six Week Price Change | -78.69% |
| Five Day Price Change | -11.16% |
| Fifty-Two Week Price Change | -31.81% |
| Year-to-Date Price Change | -84.94% |
| Month-to-Date Price Change | -16.67% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.14401 USD |
| Book Value Per Share (Most Recent Quarter) | 0.13187 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.11788 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.10569 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.44043 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00135 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.0021 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | 0 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.66037 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.48986 USD |
| Normalized (Last Fiscal Year) | -0.67561 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.66037 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.48986 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.66037 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.48986 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.06249 USD |
| Cash Per Share (Most Recent Quarter) | 0.0562 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.65157 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.45899 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.32697 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -15,582 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -22,414.13% |
| Pretax Margin (Last Fiscal Year) | -49,073.40% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -41,295.25% |
| Operating Margin (Trailing Twelve Months) | -20,104.91% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -49,073.40% |
| Net Profit Margin (Trailing Twelve Months) | -22,414.13% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 354.91% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 1,360.45% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 85.50% |
| EPS Change (Trailing Twelve Months) | 43.81% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 4 |
| Price to Tangible Book (Most Recent Quarter) | 4 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -1,216,620 |
| Net Debt (Last Fiscal Year) | -909,520 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 526 |
| Price to Sales (Trailing Twelve Months) | 229 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 |
| Current Ratio (Most Recent Quarter) | 6 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -6,466,470 |
| Free Cash Flow (Trailing Twelve Months) | -6,098,760 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -5 |
| Net Interest Coverage (Trailing Twelve Months) | -9 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 13 |
| Total Debt to Equity (Most Recent Quarter) | 3 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -156.40% |
| Return on Assets (Trailing Twelve Months) | -163.16% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -230.77% |
| Return on Equity (Trailing Twelve Months) | -293.27% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -211.46% |
| Return on Investment (Trailing Twelve Months) | -268.73% |
| Return on Investment (5 Year) | -99,999.99% |